Mitchell Sinkler & Starr Dexcom Inc Transaction History

Mitchell Sinkler & Starr

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$110.31 - $140.45 $132,372 - $168,540	1,200 Added 73.26%	2,838 $321,000
Q1 2024 Apr 30, 2024	SELL	$114.22 - $140.1 $784,919 - $962,767	-6,872 Reduced 80.75%	1,638 $227,000
Q4 2023 Feb 12, 2024	BUY	$75.49 - $124.16 $144,940 - $238,387	1,920 Added 29.14%	8,510 $1.06 Million
Q3 2023 Nov 01, 2023	BUY	$86.06 - $137.93 $325,306 - $521,375	3,780 Added 134.52%	6,590 $614,000
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $28,288 - $33,434	272 Added 10.72%	2,810 $326,000
Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $215,679 - $311,336	2,538 New	2,538 $287,000
Q2 2022 Jul 21, 2022	SELL	$67.99 - $132.89 $29,031 - $56,744	-427 Closed	0 $0
Q3 2021 Oct 12, 2021	BUY	$106.71 - $143.18 $45,565 - $61,137	427 New	427 $234,000

1,016

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Mitchell Sinkler & Starr, based on Form 13F filings with the SEC.

Stay updated on Mitchell Sinkler & Starr with notifications on news.